Global Prostate Cancer Therapeutics Market Size & Outlook
Global prostate cancer therapeutics market, 2018-2030 (US$M)
Related Markets
Global prostate cancer therapeutics market highlights
- The global prostate cancer therapeutics market generated a revenue of USD 11,301.3 million in 2022 and is expected to reach USD 21,483.3 million by 2030.
- The market is expected to grow at a CAGR (2023 - 2030) of 8.4% by 2030.
- In terms of segment, hormonal therapy accounted for a revenue of USD 9,993.0 million in 2022.
- Hormonal Therapy is the most lucrative drug class segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2022.
- Country-wise, Canada is expected to register the highest CAGR from 2023 to 2030.
Global data book summary
| Market revenue in 2022 | USD 11,301.3 million |
| Market revenue in 2030 | USD 21,483.3 million |
| Growth rate | 8.4% (CAGR from 2022 to 2030) |
| Largest segment | Hormonal therapy |
| Fastest growing segment | Hormonal Therapy |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy, Other Drug Class, Hormonal Therapy |
Other key industry trends
- In terms of revenue, the North America accounted for 41.1% of the global prostate cancer therapeutics market in 2022.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
- By country, Canada is the fastest growing regional market and is projected to reach USD 728.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Prostate Cancer Therapeutics Market Scope
Prostate Cancer Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Global prostate cancer therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to prostate cancer therapeutics market will help companies and investors design strategic landscapes.
Hormonal therapy was the largest segment with a revenue share of 88.42% in 2022. Horizon Databook has segmented the Global prostate cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy, other drug class, hormonal therapy covering the revenue growth of each sub-segment from 2018 to 2030.
- Global Prostate Cancer Therapeutics Drug Class Outlook (Revenue, USD Million, 2018-2030)
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Other Drug Class
- Hormonal Therapy
- Gonax
- Vantas
- Eligard
- Decapeptyl
- Xtandi
- Lupron
- Zoladex
- Zytiga
- Other Hormonal Therapies
- Global Prostate Cancer Therapeutics Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
Reasons to subscribe to Global prostate cancer therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global prostate cancer therapeutics market databook
-
Our clientele includes a mix of prostate cancer therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global prostate cancer therapeutics market , including forecasts for subscribers. This global databook contains high-level insights into Global prostate cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Global prostate cancer therapeutics market size, by regions, 2018-2030 (US$M)
Top 10 countries: Prostate cancer therapeutics market size, 2022 (US$M)
Global prostate cancer therapeutics market share, by drug class, 2022 & 2030 (%, US$M)
Prostate cancer therapeutics market: Opportunity assessment by country
Global prostate cancer therapeutics market, by region, 2022 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
